Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Organometallic antitumour agents with alternative modes of action

Casini, Angela, Hartinger, Christian G., Nazaroy, Alexey A. and Dyson, Paul J. 2010. Organometallic antitumour agents with alternative modes of action. In: Jaouen, Gerard and Metzler-Nolte, Nils eds. Medicinal Organometallic Chemistry, Topics in Organometallic Chemistry, vol. 32. Springer, pp. 57-80. (10.1007/978-3-642-13185-1_3)

Full text not available from this repository.


The therapeutic index of drugs that target DNA, a ubiquitous target present in nearly all cells, is low. Nevertheless, DNA has remained the primary target for medicinal chemists developing metal-based anticancer drugs, although DNA has been essentially abandoned in favour of non-genomic targets by medicinal chemists developing organic drugs. A number of organometallic drugs that target proteins/enzymes have been developed and these compounds, based on ruthenium, osmium and gold, are described in this chapter. Targets include cathepsin B, thioredoxin reductases, multidrug resistance protein (Pgp), glutathione S-transferases and kinases. It is found that compounds that inhibit these various targets are active against metastatic tumours, or tumours that are resistant to classical DNA damaging agents such as cisplatin, and therefore offer considerable potential in clinical applications.

Item Type: Book Section
Date Type: Publication
Status: Published
Schools: Chemistry
Subjects: Q Science > QD Chemistry
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Springer
ISBN: 978-3-642-13184-4
Last Modified: 23 Jul 2020 01:45

Citation Data

Cited 71 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item